Related Experiment Video
Updated: Mar 15, 2026
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
29.6K
Integrated Molecular and Functional Characterization of Cervical Small-Cell Neuroendocrine Carcinoma Using a 3D
Hasibul Islam Sohel1, Umme Farzana Zahan1, Masako Ishikawa1
1Department of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.
International Journal of Molecular Sciences
|March 14, 2026
Summary
This study developed new organoid and xenograft models for cervical small-cell neuroendocrine carcinoma (SCNEC), a rare cancer. These models accurately reflect the disease, aiding research into targeted therapies for HPV-associated SCNEC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cervical small-cell neuroendocrine carcinoma (SCNEC) is rare, aggressive, and understudied, with limited treatment options.
- High-risk human papillomavirus (HPV) infection is frequently associated with SCNEC.
- Therapeutic challenges arise due to SCNEC's low incidence and high metastatic potential.
Purpose of the Study:
- To molecularly and functionally characterize SCNEC.
- To establish and validate patient-derived organoid and xenograft models for SCNEC research.
- To support the development of informed therapeutic strategies for SCNEC.
Main Methods:
- Generated organoids, spheroids, and organoid-derived xenografts from a cervical SCNEC biopsy.
- Evaluated model fidelity through histopathology and immunohistochemistry.
- Assessed HPV status, viral-host integration, somatic variants, copy-number alterations (using WES), and drug responses.
Main Results:
- Organoid and xenograft models faithfully recapitulated SCNEC features, including neuroendocrine differentiation and high proliferation.
- HPV18 infection and integration at chr8 (8q24.21) with increased MYC expression were conserved.
- Shared somatic variants (including PIK3CA mutation) and copy-number alterations (PIK3CA, TERT, MYC gains; TP53 loss) were identified across models.
- Models showed sensitivity to conventional cytotoxic agents and an mTOR inhibitor.
Conclusions:
- The study presents the first integrated molecular and functional analyses of patient tumors and matched SCNEC models.
- These validated models serve as robust resources for mechanistic studies of SCNEC.
- The findings pave the way for precision therapeutic strategies for this rare cervical cancer.
